Immunotherapy: Transformation of Therapies for Blood Cancer

This webcast is certified for credit.

Release date: February 15, 2017 | Expiration date: February 15, 2018

OVERVIEW

To learn more about the field of immunology, view this webcast of the symposium Immunotherapy: Transformation of Therapies for Blood Cancer held December 2, 2016, in San Diego, California. The symposium was designed to provide a deeper understanding about how to harness the body’s own defenses to improve outcomes for patients with hematologic malignancies. Some of the most promising areas of research and emerging immunotherapies include tumor-specific T-cell–directed therapies, immunocheckpoint regulators, small molecule immunomodulatory drugs, specific antibodies that engage tumor and immune cells, and vaccines with neo-antigens. With recent approvals of several immunotherapies for the treatment of hematologic malignancies researchers and clinicians must stay informed about currently available agents, emerging research in immunotherapy, and ongoing clinical trials to achieve optimal outcomes for patients.

There is no fee for viewing this webcast or for downloading the slides; both materials will be available online through February 2018.

TARGET AUDIENCE

This activity is designed for hematologists and oncologists who diagnose and treat patients with hematologic malignancies, allied health care professionals involved with and/or interested in patients with hematologic malignancies, and researchers studying hematologic malignancies.

EDUCATIONAL OBJECTIVES

The activity was designed to help clinicians:

  • Interpret the clinical significance of recent advances in immunology and approved immunotherapeutics
  • Evaluate the current status and therapeutic potential of diverse immunotherapies for hematologic malignancies
  • Assess the safety and efficacy of immunotherapies and immunomodulatory drugs

FACULTY

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

All disclosed conflicts of interest have been resolved by independent content review.

DISCLOSURE OF OFF-LABEL USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Bio Ascend does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of Bio Ascend. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

SYMPOSIUM CHAIR
Renier J. Brentjens, MD, PhD
Associate Member
Memorial Sloan Kettering Cancer Center
Associate Professor, Department of Medicine
Faculty Member, Pharmacology
Weill Medical College
Cornell University
New York, New York

Disclosures: Consultant Fees: Juno Therapeutics, Inc.
Scientific Co-founder: Juno Therapeutics, Inc.
Stockholder: Juno Therapeutics, Inc.

Philippe Armand, MD, PhD
Senior Physician, Medical Oncology
Member, Lymphoma and Myeloma Program
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Disclosures: Consultant Fees: Bristol-Myers Squibb Company, Infinity Pharmaceuticals, Inc., Merck & Co., Inc.
Grants/Research Support: Bristol-Myers Squibb Company, Merck & Co., Inc., Sigma-Tau Pharmaceuticals, Inc., Sequenta, Inc., Adaptive Biotechnologies, Tensha Therapeutics Inc., Roche.

Carl H. June, MD
Richard W. Vague Professor in Immunotherapy
Department of Pathology and Laboratory Medicine
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Disclosures: Grants/Research Support: Novartis
Royalty Recipient: Novartis
Stockholder: Tmunity Therapeutics, Inc.

Ronald Levy, MD
Robert K. and Helen K. Summy Professor of Medicine
Director, Lymphoma Program
Stanford University School of Medicine
Associate Director, Translational Science
Stanford Cancer Institute
Stanford, California

Disclosures: Consultant Fees: BeiGene, Corvus Pharmaceuticals, Five Prime Therapeutics, Inc., Immune Design, Innate Pharma, Kite Pharma
Grants/Research Support: Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Pfizer Inc, Pharmacyclics LLC
Stockholder: Merck & Co., Inc.

Drew M. Pardoll, MD, PhD
Abeloff Professor of Oncology, Medicine,
Pathology and Molecular Biology and Genetics
Co-Director, Cancer Immunology and Hematopoiesis Program
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosures: Grants/Research Support: Bristol-Myers Squibb Company
Holder of Intellectual Property Rights: Bristol-Myers Squibb Company, MedImmune/AstraZeneca
Consultant Fees: Amgen Inc., MedImmune/AstraZeneca, GlaxoSmithKline plc., Pfizer Inc

Roland B. Walter, MD, PhD, MS
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Associate Professor of Medicine, Division of Hematology
University of Washington School of Medicine
Adjunct Associate Professor, Department of Epidemiology
School of Public Health
Seattle, Washington

Disclosures: Grants/Research Support: Amgen Inc., Amphivena Therapeutics, Inc., Covagen AG, Seattle Genetics, Inc.
Consultant Fees: Amgen Inc., Amphivena Therapeutics, Inc., Covagen AG, Emergent Biosolutions Inc, Janssen Global Services, LLC, Pfizer Inc, Seattle Genetics, Inc.

 

TOPICS

Adoptive Cellular Therapies
Carl H. June, MD

Bispecific Antibody Therapy of Acute Leukemia
Roland B. Walter, MD, PhD, MS

Checkpoint Blockade*
Philippe Armand, MD, PhD

Rational Combinations With Immunotherapeutics
Ronald Levy, MD

Established and Novel Targets in Immunotherapy
Drew M. Pardoll, MD, PhD

Recap of Key Points
Renier J. Brentjens, MD, PhD

*Slides will not be released for this presentation

 

CONTINUING EDUCATION

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education, The Leukemia & Lymphoma Society, and Bio Ascend.

 

SUPPORT

This activity is coordinated and supported in part by The Leukemia & Lymphoma Society. Educational grant support is provided by Acerta Pharma – A member of the AstraZeneca Group, Celgene Corporation, and KITE Pharma.

Press the button below to continue to the webcast.

Begin Activity

Copyright © 2017 Bio Ascend LLC

Bio Ascend LLC
980 N Michigan Avenue, Suite 1400
Chicago, IL 60611
(p)773-304-5019
(f)312-277-6893 | info@bioascend.com | cme@bioascend.com | program@bioascend.com

Bio Ascend LLC observes pharmaceutical industry compliance and regulatory guidelines.